Vericel (VCEL) Total Non-Current Liabilities (2010 - 2026)

Vericel (VCEL) posted Total Non-Current Liabilities of $130.9 million for Q2 2026, up 2.66% sequentially from $127.5 million in Q1 2026, and up 2.96% YoY from $127.1 million in Q2 2025.

Vericel (VCEL) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends

Vericel has reported Total Non-Current Liabilities for 17 years, with the latest figure at $130.9 million in Q2 2026.

  • Quarterly Total Non-Current Liabilities rose 2.96% year-over-year to $130.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $130.9 million (up 2.96% YoY) and the FY2025 annual result came in at $131.4 million, down 6.04% from the prior year.
  • Total Non-Current Liabilities climbed to $130.9 million in Q2 2026 per VCEL's latest filing, from $127.5 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $139.9 million in Q4 2024 and troughed at $67.8 million in Q1 2022.
  • A 5-year average of $114.4 million and a median of $127.3 million in 2025 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities surged 61.98% in 2023, then slipped 6.04% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $80.7 million in 2022, then soared by 58.06% to $127.6 million in 2023, then climbed by 9.62% to $139.9 million in 2024, then declined by 6.04% to $131.4 million in 2025, then declined by 0.4% to $130.9 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $130.9 million, $127.5 million, and $131.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 5.92 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 7.74 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 40.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 1.53 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 1.88 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -
7 Royalty Pharma 33.72 Bn 35.84 Bn - 9.32 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.20 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.17 Bn
10 Vericel 2.26 Bn 2.10 Bn 56.40 Mn 130.91 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 130.91 Mn
Mar 31, 2026 127.52 Mn
Dec 31, 2025 131.43 Mn
Sep 30, 2025 129.74 Mn
Jun 30, 2025 127.14 Mn
Mar 31, 2025 127.25 Mn
Dec 31, 2024 139.88 Mn
Sep 30, 2024 132.69 Mn
Jun 30, 2024 133.66 Mn
Mar 31, 2024 122.61 Mn
Dec 31, 2023 127.61 Mn
Sep 30, 2023 113.68 Mn
Jun 30, 2023 111.76 Mn
Dec 31, 2022 80.73 Mn
Sep 30, 2022 70.18 Mn
Jun 30, 2022 69.98 Mn
Mar 31, 2022 67.78 Mn
Dec 31, 2021 73.20 Mn
Sep 30, 2021 67.32 Mn
Jun 30, 2021 70.79 Mn